NCT05606965View on ClinicalTrials.gov

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

PHASE2RecruitingINTERVENTIONAL
Enrollment

325

Participants

Timeline

Start Date

November 2, 2022

Primary Completion Date

November 11, 2025

Study Completion Date

November 11, 2025

Conditions
Influenza
Interventions
BIOLOGICAL

mRNA-1010

Sterile liquid for injection

BIOLOGICAL

Egg-based Quadrivalent Influenza Vaccine

Sterile suspension for injection

BIOLOGICAL

Adjuvanted Quadrivalent Influenza Vaccine

Sterile injectable emulsion

BIOLOGICAL

Inactivated Influenza Vaccine

Sterile suspension for injection

BIOLOGICAL

mRNA-1345

Sterile liquid for injection

BIOLOGICAL

mRNA-1045

Sterile liquid for injection

Trial Locations (1)

63110

RECRUITING

Washington University in St. Louis, St Louis

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY